Literature DB >> 30446983

Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience.

R Figueroa1, A Alfonso1, J López-Picazo2, I Gil-Bazo2, A García-Mouriz3, J Hermida4,5, J A Páramo1,5, R Lecumberri6,7.   

Abstract

PURPOSE: Thromboprophylaxis use among medical inpatients, including cancer patients, is suboptimal. We aimed to evaluate the impact of a novel multiscreen version (v2.0) of an e-alert system for VTE prevention in hospitalised cancer medical patients compared to the original software.
METHODS: Prospective study including 989 consecutive adult cancer patients with high-risk of VTE. Patients were followed-up 30 days post-discharge. Two periods were defined, according to the operative software.
RESULTS: E-alert v2.0 was associated with an increase in the use of LMWH prophylaxis (65.5% vs. 72.0%); risk difference (95% CI) 0.064 (0.0043-0.12). Only 16% of patients in whom LMWH prophylaxis was not prescribed lacked a contraindication. No significant differences in the rates of VTE (2.9% vs. 3.2%) and major bleeding (2.7% vs. 4.0%) were observed.
CONCLUSIONS: E-alert v2.0 further increased the use of appropriate thromboprophylaxis in hospitalised cancer patients, although was not associated with a reduction in VTE incidence.

Entities:  

Keywords:  Cancer; Electronic alerts; Low molecular weight heparin; Prophylaxis; Venous thromboembolism

Mesh:

Substances:

Year:  2018        PMID: 30446983     DOI: 10.1007/s12094-018-1986-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  18 in total

1.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Economic impact of an electronic alert system to prevent venous thromboembolism in hospitalised patients.

Authors:  R Lecumberri; E Panizo; A Gomez-Guiu; S Varea; E García-Quetglas; M Serrano; A García-Mouriz; M Marqués; A Gómez-Outes; J A Páramo
Journal:  J Thromb Haemost       Date:  2011-06       Impact factor: 5.824

3.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.

Authors:  S Schulman; C Kearon
Journal:  J Thromb Haemost       Date:  2005-04       Impact factor: 5.824

4.  Electronic alerts to prevent venous thromboembolism among hospitalized patients.

Authors:  Nils Kucher; Sophia Koo; Rene Quiroz; Joshua M Cooper; Marilyn D Paterno; Boris Soukonnikov; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

5.  Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.

Authors:  Alok A Khorana; Charles W Francis; Eva Culakova; Nicole M Kuderer; Gary H Lyman
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

6.  Maintained effectiveness of an electronic alert system to prevent venous thromboembolism among hospitalized patients.

Authors:  Ramón Lecumberri; Margarita Marqués; María Teresa Díaz-Navarlaz; Elena Panizo; Jon Toledo; Alberto García-Mouriz; José A Páramo
Journal:  Thromb Haemost       Date:  2008-10       Impact factor: 5.249

7.  Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER).

Authors:  N Kucher; D Spirk; I Baumgartner; L Mazzolai; W Korte; D Nobel; M Banyai; H Bounameaux
Journal:  Ann Oncol       Date:  2009-10-14       Impact factor: 32.976

8.  Inpatient thromboprophylaxis use in U.S. hospitals: adherence to the seventh American College of Chest Physician's recommendations for at-risk medical and surgical patients.

Authors:  Alpesh N Amin; Stephen Stemkowski; Jay Lin; Guiping Yang
Journal:  J Hosp Med       Date:  2009-10       Impact factor: 2.960

9.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

Authors:  Paolo Prandoni; Anthonie W A Lensing; Andrea Piccioli; Enrico Bernardi; Paolo Simioni; Bruno Girolami; Antonio Marchiori; Paola Sabbion; Martin H Prins; Franco Noventa; Antonio Girolami
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113

10.  Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study.

Authors:  Alexander T Cohen; Victor F Tapson; Jean-Francois Bergmann; Samuel Z Goldhaber; Ajay K Kakkar; Bruno Deslandes; Wei Huang; Maksim Zayaruzny; Leigh Emery; Frederick A Anderson
Journal:  Lancet       Date:  2008-02-02       Impact factor: 79.321

View more
  1 in total

1.  Thromboprophylaxis in Patients With Cancer and COVID-19.

Authors:  Ramón Lecumberri; María Marcos-Jubilar; Carolina Guillén
Journal:  Arch Bronconeumol       Date:  2022-09-08       Impact factor: 6.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.